Pharmacogenetics of response to methylphenidate in adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD): A systematic review

Imagem de Miniatura
Arquivos
art_CONTINI_Pharmacogenetics_of_response_to_methylphenidate_in_adult_patients_2013.PDF (239.54 KB)
Citações na Scopus
28
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
CONTINI, Veronica
ROVARIS, Diego L.
VICTOR, Marcelo M.
GREVET, Eugenio H.
BAU, Claiton H. D.
Citação
EUROPEAN NEUROPSYCHOPHARMACOLOGY, v.23, n.6, p.555-560, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Methylphenidate (MPH) is a first line option in the psychopharmacologic treatment of adults with Attention-Deficit/Hyperactivity Disorder (ADHD). However, there is a considerable proportion of adult patients who do not respond to treatment with MPH or discontinue drug therapy. Since effects of genetic variants in the response to MPH treatment might explain these negative outcomes, we conducted an electronic systematic search of MEDLINE-indexed literature looking for articles containing information about pharmacogenetics of ADHD in adults published until January, 2012. The keywords used were 'ADHD', 'Attention-Deficit/Hyperactivity Disorder' and 'gene' in combination with methylphenidate, amphetamine or atomoxetine. Only 5 pharmacogenetic studies on adult ADHD met inclusion criteria. The results evidenced that most findings obtained so far are negative, and all studies focused on MPH response. There is only one positive result, for a polymorphism at the dopamine transporter gene (DAT1) gene. The current state of the art in adult ADHD implies that pharmacogenetic tests are far from routine clinical practice. However, the integration of these studies with neuroimaging and neuropsycholcigical tests may help to understand mechanisms of drug action and the pathophysiology of ADHD.
Palavras-chave
Attention-Deficit/Hyperactivity Disorder, ADHD, Pharmacogenetics, Methylphenidate, Pharmacogenomics, Genetics
URI
https://observatorio.fm.usp.br/handle/OPI/7745
Referências
  1. Arnsten AFT, 2011, PHARMACOL BIOCHEM BE, V99, P211, DOI 10.1016/j.pbb.2011.01.020
  2. Buitelaar JK, 2009, NEUROPSYCH DIS TREAT, V5, P457
  3. Castells X, 2011, CNS DRUGS, V25, P157, DOI 10.2165/11539440-000000000-00000
  4. Contini V, 2010, J NEURAL TRANSM, V117, P269, DOI 10.1007/s00702-009-0362-2
  5. Contini V, 2011, EUR ARCH PSY CLIN N, V261, P205, DOI 10.1007/s00406-010-0172-4
  6. Contini V., J CLIN PSYC IN PRESS
  7. Faraone SV, 2004, J CLIN PSYCHOPHARM, V24, P24, DOI 10.1097/01.jcp.0000108984.11879.95
  8. Froehlich TE, 2010, CNS DRUGS, V24, P99, DOI 10.2165/11530290-000000000-00000
  9. Gehricke Jean-G, 2007, Nicotine Tob Res, V9 Suppl 4, pS523, DOI 10.1080/14622200701685039
  10. Gehricke JG, 2006, NICOTINE TOB RES, V8, P37, DOI 10.1080/14622200500431619
  11. Johnson JA, 2010, PHARMACOGENOMICS, V11, P487, DOI [10.2217/pgs.10.34, 10.2217/PGS.10.34]
  12. Kieling C, 2010, PHARMACOGENOMICS, V11, P407, DOI [10.2217/pgs.10.28, 10.2217/PGS.10.28]
  13. Koesters M, 2009, J PSYCHOPHARMACOL, V23, P733, DOI 10.1177/0269881108092338
  14. Kooij JS, 2008, AM J MED GENET B, V147B, P201, DOI 10.1002/ajmg.b.30586
  15. Levin ED, 1998, PSYCHOPHARMACOLOGY, V140, P135, DOI 10.1007/s002130050750
  16. Ma Q, 2011, PHARMACOL REV, V63, P437, DOI 10.1124/pr.110.003533
  17. Manolopoulos VG, 2010, PHARMACOGENOMICS, V11, P493, DOI [10.2217/pgs.10.31, 10.2217/PGS.10.31]
  18. MENKES MM, 1967, PEDIATRICS, V39, P393
  19. Mick E, 2008, AM J MED GENET B, V147B, P1412, DOI 10.1002/ajmg.b.30865
  20. Mick E, 2006, AM J MED GENET B, V141B, P890, DOI 10.1002/ajmg.b.30376
  21. Mroziewicz Margaret, 2010, Addict Sci Clin Pract, V5, P17
  22. Nutt DJ, 2007, J PSYCHOPHARMACOL, V21, P10, DOI 10.1177/0269881106073219
  23. Polanczyk G, 2010, CURR PHARM DESIGN, V16, P2462
  24. Purper-Ouakil D, 2008, AM J MED GENET B, V147B, P1425, DOI 10.1002/ajmg.b.30809
  25. Verde Z, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011210
  26. Victor MM, 2009, J CLIN PSYCHOPHARM, V29, P614, DOI 10.1097/JCP.0b013e3181c00b1e
  27. Weinshilboum R, 2003, NEW ENGL J MED, V348, P529
  28. Wigal SB, 2009, CNS DRUGS, V23, P21, DOI 10.2165/00023210-200923000-00004
  29. Wilens TE, 2008, J CLIN PSYCHOPHARM, V28, pS46, DOI 10.1097/JCP.0b013e318173312f
  30. Winsberg BG, 1999, J AM ACAD CHILD PSY, V38, P1474, DOI 10.1097/00004583-199912000-00006
  31. WOOD DR, 1976, ARCH GEN PSYCHIAT, V33, P1453
  32. Yee SW, 2010, PHARMACOGENOMICS, V11, P475, DOI [10.2217/pgs.10.22, 10.2217/PGS.10.22]

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros